Greenphire Supports Proposed EU Legislation to Reduce Clinical Trial Administration

King of Prussia, PA (25 Jul 2012) – The European Commission recently announced proposals to address increasing administrative costs and a decline in the number of cross-border clinical trials conducted in the European Union. The proposed legislation, expected to be enacted by 2016, aims to speed up authorization and reporting procedures while ensuring patient safety and data quality. Greenphire, the global leader in clinical payment technologies, today affirmed its support of the new regulation and its focus on alleviating the administrative burden of trials taking place across multiple geographies. Greenphire is committed to reducing administration associated with clinical payment processes through innovative platforms such as its eClinicalGPS technology.

The European Commission reports that the number of clinical trials carried out in the European Union between 2007 and 2011 has dropped by 25 per cent, with applications down from over 5,000 in 2007 to 3,800 in 2011, while administrative costs have doubled. This trend has been attributed to the 2001 Clinical Trials Directive, which imposed tighter controls on monitoring and reporting drug trials. Currently, companies or researchers seeking to conduct clinical trials in more than one EU country must submit separate applications and reports in each country. Under the proposed new system, applicants will only have to submit this information once. The new regulation streamlines this process in order to make pan-Europe an attractive place to conduct trials. According to John Dalli, European Commissioner for Health and Consumer Policy, the new legislation could save over 800 million euros per year in regulatory costs.

John Blakeley, Chief Commercial Officer of Greenphire, voiced his support of the proposed regulation, saying: “Greenphire welcomes new measures to facilitate the implementation of cross-border clinical trials and ease administrative burdens. In addition to achieving its main goal, this legislation will also benefit research in areas such as rare diseases where there may be only a few subjects in each country, and which may otherwise face bureaucratic obstacles."

Blakeley continued, "Greenphire currently helps trial sponsors to implement studies across multiple geographies through our global web-based clinical payment management platform, the eClinicalGPS. In contrast to  more expensive and time consuming manual paper-based payment processes currently used in clinical research, Greenphire's automated electronic system enables sponsors and CROs to automatically distribute payments in over 200 currencies to all investigators, sites and vendors globally.”

To arrange an interview with John Blakeley, please contact the Greenphire team at The Scott Partnership by emailing greenphire@scottpr.com or calling +44 1477 539539.

For further information on Greenphire and its innovative solutions please email: mailto:sales@greenphire.com, call +1 215.948.9251or visit www.greenphire.com.

About Greenphire:

Greenphire is a clinical technology company, headquartered in suburban Philadelphia, which offers web-based clinical payment technology platforms for use by research sites, research universities, sponsors and CROs. Greenphire's clinical payment technologies are designed to automate calculation workflows, approval workflows and execute payments to patients, research sites and clinical vendors on a global basis, in local currency, through a single web portal platform.  Greenphire's technologies are designed to streamline operations, reduce administration, reduce costs and provide analytics and other business intelligence that has not been readily available in the past.

Greenphire's global patient payment technology also incorporates automated electronic messaging functionality that, when combined with payment functionality, effectively improves the clinical experience for patients and sites, drives positive patient behavior to increase patient retention and protocol compliance, and significantly reduces site and study team administration. Learn more about Greenphire’s innovative clinical payment solutions at www.greenphire.com.

Vodafone and Exco InTouch partner to develop a Patient Reported Outcomes solution that will transform patient engagement in clinical trials

(26 June 2012) Vodafone, one of the world's largest mobile communications companies, announced today that it has signed an agreement with Exco InTouch, a leading provider of compliant, interactive mobile patient management solutions.

Together they will deliver Vodafone Patient Reported Outcomes (Vodafone PRO), a solution which has the potential to radically improve patient compliance and data quality in clinical research.

Vodafone PRO enables high quality data to be gathered as trial participants can report their experiences quickly and easily using their own mobile phone.  The service will be available on a global scale, benefiting from Vodafone’s international footprint and in-depth mobile and consumer insight, along with Exco InTouch’s extensive background in patient engagement. As more than 85% of the world’s population now own a mobile phone, the solution is using accessible technology that is firmly embedded in many people’s lives.

Exco InTouch’s solutions have been chosen by Vodafone as they provide simple, non-intrusive and compliant channels of communication. This enables sponsors and Contract Research Organisations to find and retain the right patients through engaging interactions and improved patient experience as well as offering customisable solutions to facilitate the collection of high quality patient data.

Axel Nemetz, Head of mHealth Solutions for Vodafone, said. “With this collaboration, Vodafone is confident that we can offer our clients the most innovative and effective clinical research solutions available in the global market. Our involvement will enable sponsors to choose our services for entire therapeutic areas around the world.” The initiative supports Vodafone’s strategy to expand its global and scalable healthcare services.

Tim Davis, CEO, Exco InTouch, comments: “Exco InTouch is delighted to enter into this complementary agreement with Vodafone. It demonstrates the extent to which mobile phone technology is increasingly being recognised by large pharmaceutical companies as an effective tool for the collection of clinical trial data. As a result of the partnership, research sponsors will be able to monitor safety and manage compliance in real time. This will make clinical trials easier and safer for patients, while enabling researchers to collect and process data quickly, accurately and reliably.”

Vodafone PRO can be configured for different study protocols in all phases of clinical research to collect crucial patient reported end point data. This scalable solution allows large volumes of high quality patient data to be securely transferred, validated and analysed in clinical trials. Vodafone PRO will make it easier for sponsors to retain and track people participating in trials and, through the patient-centred approach, is designed to improve the quality of data captured.

To learn more about this new partnership agreement, visit the Exco InTouch booth (#3201) at the DIA Annual Meeting, Philadelphia, 24-28 June, 2012.

For further information on the Exco InTouch range of solutions, please call +44 1279 709 040 or +1 877 327 5777 or visit www.excointouch.co.uk.

For further information on Vodafone mHealth Solutions, visit http://mhealth.vodafone.com.

-ENDS-

For further press information please contact: Michelle Valentine, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA Tel: +44 1477 539539 Fax: +44 1477 539540 e-mail: exco@scottpr.com

About Exco InTouch

Exco InTouch is the trusted global innovator of regulatory compliant, mobile patient engagement solutions for life sciences and healthcare companies involved in clinical, late phase and mHealth research. Using a combination of patented software and services delivered in a cloud environment, Exco’s solutions can be utilised on any electronic device. This safe, secure platform facilitates compliant patient communication across the clinical development process from early phase development right through to long term studies and mHealth. As a result, Exco can help its customers to improve clinical outcomes by putting the patient at the heart of a study and enhancing the overall patient experience.

Exco’s solutions are currently being used by hundreds of thousands of patients in over seventy countries, delivered in the local language and are fully compliant with HIPAA regulations, FDA CFR 21 Part 11 and all electronic communication privacy directives.

About Vodafone

Vodafone is one of the world's largest mobile communications companies by revenue with approximately 404 million customers in its controlled and jointly controlled markets as at 31 March 2012. Vodafone currently has equity interests in over 30 countries across five continents and more than 40 partner networks worldwide. For more information, please visit www.vodafone.com.

Greenphire awarded the PACT Enterprise Award for Technology Startup

King of Prussia, PA, 17 May, 2012 – Greenphire, the leading provider of payment technologies for the clinical trials industry, announced today that it has been awarded the Philadelphia Alliance for Capital and Technologies (PACT) Enterprise Award in the Technology Startup division. Greenphire and other Enterprise Award winners and finalists were recognized at the 19th Annual Enterprise Awards gala of 1,200 prominent business leaders on May 3, 2012 in Philadelphia.

The Enterprise Awards honor exceptional technology and life sciences companies and entrepreneurs in the greater Philadelphia region each year, with past ceremonies recognizing pillars of the healthcare and clinical trials community including Siemens Healthcare, BioClinica, and Shire Pharmaceuticals. The recognition followed an extensive vetting and selection process based on the finalist companies’ established success in delivering an innovative product, potential for growth, managerial ability, and demonstration of success via significant business milestones such as raising capital and achieving revenue growth.

Speaking at this year’s awards ceremony, PACT President and CEO Dean Miller commented on the role of Greenphire and other promising startup companies, saying “These startups are doing tremendous work that has great potential. For our region, they create jobs and provide business opportunity. But on a much wider scale they work to help improve the human condition…We’ve seen such a flurry of business activity over the past year, and businesses are growing and innovating. Venture money is starting to flow again, deal flow is ramping up, new products are rolling out the door, new partnerships are developing, and companies are hiring again. We can certainly feel the energy in the room. And it is that same energy and success that defines (Greenphire).”

Greenphire Co-Founder and CEO Sam Whitaker similarly expressed the company’s enthusiasm with the Enterprise Award, saying “It’s exciting to be recognized for the Enterprise Award. I’ve seen this award identify promising and ultimately thriving technology companies for years, and it’s a thrill for Greenphire to be a part of it this time around. It’s a true honor for me and the company, given the credibility and experience which PACT embodies.”

A full list of this year’s Enterprise Award winners and finalists can be found on the PACT website at http://pact.gpcc.com/.

About Greenphire

Greenphire’s clinical payment and communication solutions take a patient-centric and site-centric approach to driving data integrity and data completeness for sponsor, CRO, research university, and clinical research site clients. Greenphire’s web-based technologies are designed to improve the clinical experience for patients and sites, drive positive patient behavior, increase patient retention and compliance, and significantly reduce site and study team administration associated with patient payments and communication. Greenphire’s strategy is driven by the philosophy that empowered, satisfied patients and sites will deliver more consistent and better quality clinical data, which will in turn benefit both site coordinators and study teams. Learn more about Greenphire’s innovative clinical solutions at www.greenphire.com.

For further information on Greenphire and its innovative solutions please email: sales@greenphire.com, call +1 215-609-4640 or visit www.greenphire.com.

For further press information please contact Celine Goodier, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom. Phone +44 1477 539539, Fax +44 1477 539540, Email greenphire@scottpr.com

Greenphire Selected by AlwaysOn as a Venture Summit Mid-Atlantic 100 Winner

King of Prussia, PA, 13 December, 2011 – Greenphire, the leading provider of payment technologies for the clinical trials industry, today announced that it has been chosen by AlwaysOn as one of the Venture Summit Mid-Atlantic 100 winners. Inclusion in the Venture Summit Mid-Atlantic 100 signifies leadership amongst its peers and game-changing approaches and technologies that are likely to disrupt existing markets and entrenched players. Greenphire was specially selected by the AlwaysOn editorial team and industry experts spanning the globe based on a set of five criteria: innovation, market potential, commercialization, stakeholder value and media buzz.

Greenphire and the Venture Summit Mid-Atlantic 100 companies were honored at the IMPACT Venture Summit Mid-Atlantic event, November 29th and 30th, 2011, at the Ritz Carlton in Philadelphia, PA.

This two-day executive event featured CEO presentations and high-level debates on the most promising emerging technologies and new entrepreneurial opportunities on the East Coast. The Greater Philadelphia Alliance for Capital and Technologies (PACT) annual venture conference, IMPACT 2011, is the most established venture conference in the northeast. For over 20 years, IMPACT has been showcasing the best and most promising investment opportunities in the technology, life sciences and clean technology sectors.

“The Venture Summit Mid-Atlantic 100 winners are transforming the mid-Atlantic region’s technology community through innovation and creativity,” said Tony Perkins, founder and editor at AlwaysOn. “The companies represent some of the highest-growth opportunities in the mid-Atlantic private company marketplace across all industry sectors, including digital media and entertainment, on-demand computing as well as greentech and the life sciences.”

The Venture Summit Mid-Atlantic 100 winners were selected from among thousands of mid-Atlantic technology companies nominated by investors, bankers, journalists and greentech industry insiders. The AlwaysOn editorial team conducted a rigorous three-month selection process to finalize the 2011 list.

Greenphire is the leading provider of payment and communication technology solutions in the clinical trials industry. The firm was founded by Sam Whitaker and John Samar in 2008 with the vision of creating a globally scalable technology platform to allow pharmaceutical and medical device developers and clinical research sites to electronically deliver payments to investigators, vendors and trial participants. Since then, Greenphire’s technologies have been implemented to support over 60,000 clinical trial participants across 6,000 studies at 1,200 clinical trial sites.

"We're thrilled and honored to be included in AlwaysOn's Venture Summit Mid-Atlantic 100,” said Greenphire CEO Samuel Whitaker. “Greenphire's unique clinical payment solutions are a perfect fit with AlwaysOn's focus on technological innovation, and this recognition is extremely valuable as we continue to establish the Greenphire brand as the leader in developing cutting-edge clinical technology platforms."

A full list of all the Venture Summit Mid-Atlantic 100 winners can be found on the AlwaysOn website at:http://www.aonetwork.com/AOStory/Announcing-2011-Venture-Summit-Mid-Atlantic-100-Top-Private-Companies

About Greenphire
Greenphire’s clinical payment and communication solutions take a patient-centric and site-centric approach to driving data integrity and data completeness for sponsor, CRO, research university, and clinical research site clients. Greenphire’s web-based technologies are designed to improve the clinical experience for patients and sites, drive positive patient behavior, increase patient retention and compliance, and significantly reduce site and study team administration associated with patient payments and communication. Greenphire’s strategy is driven by the philosophy that empowered, satisfied patients and sites will deliver more consistent and better quality clinical data, which will in turn benefit both site coordinators and study teams. Learn more about Greenphire’s innovative clinical solutions at www.greenphire.com.

About AlwaysOn
AlwaysOn is the leading business media brand networking the Global Silicon Valley. AlwaysOn helped ignite the social media revolution in early 2003 when it launched the AlwaysOn network. In 2004, it became the first media brand to socially network its online readers and event attendees. AlwaysOn’s preeminent executive event series includes the Silicon Valley Innovation Summit, OnMedia, OnHollywood, Venture Summit Mid-Atlantic, OnDemand, Venture Summit Silicon Valley, OnMobile, and GoingGreen Silicon Valley. The AlwaysOn network and live event series continue to lead the industry by empowering its readers, event participants, sponsors, and advertisers like no other media brand.
For further information on Greenphire and its innovative solutions please email: sales@greenphire.com, call +1 215-609-4640 or visit www.greenphire.com.
For further press information please contact Celine Callender, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom. Phone +44 1477 539539, Fax +44 1477 539540, Email greenphire@scottpr.com

Greenphire Closes Series A Financing Led by FirstMark Capital

KING OF PRUSSIA, PA (September 14, 2011) – Greenphire, the leading provider of web-based payment and communication technologies for the healthcare clinical trials industry, announced today that it has completed a Series A financing led by prominent New York-based venture capital firm, FirstMark Capital.

All of Greenphire’s existing angel investors, including leading healthcare industry veterans and entrepreneurs, participated in the funding.  Gerald A.Poch, a Founder and Managing Director at FirstMark Capital, will join Greenphire’s Board of Directors alongside the company’s existing Directors—CEO Samuel Whitaker, Dr. Neil Rotherham, and David Reuter—as part of the financing.  The Series A funding will support the recent launch of Greenphire’s innovative eClinicalGPS technology, a clinical payment platform designed to automate site and vendor payments within the clinical research environment.  Additionally, the capital will be used to expand global sales and marketing initiatives for Greenphire’s flagship technology platform, the ClinCard System, which currently hosts a client base of more than 140 clinical trials sponsors, research sites, contract research organizations and research universities.

The Scott Partnership Appointed by Greenphire, Leading Provider of Clinical Payment and Technology Solutions

Cheshire, UK (April 20, 2011) - Global life sciences and technology strategic communications agency The Scott Partnership, announces that it has been appointed by Pennsylvania-based Greenphire to lead a PR campaign aimed at raising company and brand awareness. Since being founded in 2007, Greenphire's clinical payment and communication technologies have been adopted by over 100 unique clients throughout the Americas, Europe and Asia Pacific. This latest addition to The Scott Partnership's portfolio is a further step in the company's ongoing expansion, strengthening its customer base and presence in the clinical studies market.

Patients participating in clinical trials have traditionally been reimbursed for their time and expenses by paper check. This is not an efficient payment method as checks are both time- and cost-intensive to administer, and in addition can be costly for the patient as approximately 60 million Americans are currently living without a bank account. In response, Greenphire have introduced an auditable card payment and communication system called the ClinCard solution which allows the study participants to be reimbursed in real-time through a reloadable debit card. The ClinCard is coupled with protocol, appointment and financial communication custom tailored to the study, resulting in benefits of increased subject retention and protocol compliance. The ClinCard solution is currently utilized by over 35 Sponsor companies and across over 1,000 studies at present. The Scott Partnership will undertake a PR campaign that further raises the profile of the company within the clinical industry.